The investigational monoclonal antibody clesrovimab protected against respiratory syncytial virus (RSV) disease and prevented RSV hospitalizations among healthy preterm- and term infants ...

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...

In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than ...

If you continue to have this issue please contact customerservice@slackinc.com. Clesrovimab was 91% effective at preventing medically attended lower respiratory tract infections vs. placebo.

Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...

The incidence of treatment-related side effects were comparable between the clesrovimab and placebo groups, Merck said, adding that there were no treatment or RSV-related deaths during the study.

Merck’s (NYSE:MRK) monoclonal antibody clesrovimab, designed as a prophylactic against respiratory syncytial virus (RSV), has reduced the RSV-associated lower respiratory infections by roughly ...

Results from the Phase 2b/3 trial of single dose of clesrovimab in healthy preterm and full-term infants met all prespecified endpoints. Interim data showed clesrovimab had a comparable safety ...

MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-growing ...

If approved, clesrovimab has the potential to be available to help address the burden of RSV disease in the U.S. in time for the 2025-26 season RAHWAY, N.J., December 17, 2024--(BUSINESS WIRE ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Please provide your email address to receive an email when new articles are posted on . Clesrovimab is a monoclonal antibody that protects against RSV subtypes A and B. The FDA set a PDUFA date ...